Application of Nanotrap® technology for high sensitivity measurement of urinary OspA protein

Journal of Translational Medicine, 2015


Application of Nanotrap® technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis




Prompt antibiotic treatment of early stage Lyme borreliosis (LB) prevents progression to severe multisystem disease. There is a clinical need to improve the diagnostic specificity of early stage Lyme assays in the period prior to the mounting of a robust serology response. Using a novel analyte harvesting nanotechnology, Nanotrap® particles, we evaluated urinary Borrelia Outer surface protein A (OspA) C-terminus peptide in early stage LB before and after treatment, and in patients suspected of late stage disseminated LB. Conclusions: OspA urinary shedding was strongly linked to concurrent active symptoms (e.g. EM rash and arthritis), while resolution of these symptoms after therapy correlated with urinary conversion to OspA negative.



  • LinkedIn Classic
  • Twitter App Icon
  • Facebook Social Icon

9460 Innovation Drive, Manassas, VA, 20110, United States

800-615-0418 / info@ceresnano.com

© 2020 Ceres Nanosciences, Inc. All Rights Reserved